Immuron appoints LifeSci Capital as exclusive financial advisor
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has engaged LifeSci Capital as its exclusive financial advisor to assist in evaluation of strategic initiatives aimed at maximising shareholder value, the company announced on 10 November 2026.
Immuron is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
When big ASX news breaks, our subscribers know first
What the strategic process could include
Strategic initiatives under consideration may include, but are not limited to:
- Mergers
- Acquisitions
- Licensing
- Other strategic transactions
There can be no assurance that the strategic process will result in any transaction or other strategic outcome.
The LifeSci mandate follows an earlier partnering effort for the IMM-529 C. diff asset, which Immuron handed to specialist firm Pullan Consulting with the aim of securing a licensing partner for the Phase 2-ready program.
The company does not intend to provide updates on the process unless and until its Board of Directors approves a specific transaction or course of action, or the company otherwise determines that disclosure is appropriate or required.
Curious About Immuron’s Strategic Path Forward?
Immuron has appointed LifeSci Capital as exclusive financial advisor to evaluate mergers, acquisitions, licensing and other strategic transactions aimed at maximising shareholder value. The mandate builds on the earlier partnering effort for its Phase 2-ready IMM-529 C. diff program.
Investors wanting to follow the company’s developments in orally delivered polyclonal antibodies can visit the Immuron investor centre for announcements and company information. Explore the latest updates to better understand the opportunity ahead.